Last reviewed · How we verify

NCT05638412

Investigating the Impact of JASPER Behavioral Therapy in Children With Down Syndrome

Completed NA Last updated 13 April 2026
What this trial tests

NA trial testing JASPER in Down Syndrome in 103 participants. Completed in 28 May 2025.

Timeline
23 January 2023
Primary endpoint
28 May 2025
28 May 2025

Quick facts

Lead sponsorBoston Children's Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment103
Start date23 January 2023
Primary completion28 May 2025
Estimated completion28 May 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Boston Children's Hospital

Who can join

Adults 36 Months to 90 Months, any sex, with Down Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, investigators will study the impact of a 1:1 caregiver coaching intervention using the JASPER (Joint Attention, Symbolic Play, Engagement, Regulation) behavioral therapy curriculum compared to a psychoeducational curriculum that will be provided to caregivers for self-directed learning. Investigators want to determine the impact of both interventions on the child's development and behavior, and caregiver implementation of strategies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of JASPER

Trials testing the same drug.

Other recruiting trials for Down Syndrome

Currently open trials in the same condition.

Other Boston Children's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05638412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing